Biologic agents in the treatment of granulomatosis with polyangiitis.

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Granulomatosis with polyangiitis (GPA) is a type of vasculitis that affects the respiratory tract and kidneys. Without treatment, half of patients die within 6 months. Standard therapy (a daily combination of cyclophosphamide and glucocorticoids) can induce remission, but the duration is short and treatment is plagued by serious morbidity. Advances in understanding the potential target of cyclophosphamide--B cells, that indirectly give rise to antineutrophil cytoplasmic antibodies (ANCA)--led to a new B-cell-targeted strategy. We administered rituximab, an anti-B-cell agent, to patients with severe GPA and microscopic polyangiitis. Overall, rituximab matched the efficacy of cyclophosphamide in inducing remission and was superior in patients with relapsing disease. The timing of re-treatment can be individualized based on patients' B-cell counts and ANCA levels in patients with chronically relapsing GPA.

Original languageEnglish (US)
Pages (from-to)S50-53
JournalCleveland Clinic journal of medicine
Volume79 Suppl 3
StatePublished - Nov 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Biologic agents in the treatment of granulomatosis with polyangiitis.'. Together they form a unique fingerprint.

  • Cite this